Kendall A Smith, Sofija Andjelic, Zoran Popmihajlov, Liza Kelly-Rossini, Aquanette Sass, Martin Lesser, Steven Benkert, Cory Waters, Joyce Ruitenberg, Paul Bellman
{"title":"使用加那利痘疫苗和白细胞介素-2对HIV-1感染进行免疫治疗:随机试验的终止。","authors":"Kendall A Smith, Sofija Andjelic, Zoran Popmihajlov, Liza Kelly-Rossini, Aquanette Sass, Martin Lesser, Steven Benkert, Cory Waters, Joyce Ruitenberg, Paul Bellman","doi":"10.1371/journal.pctr.0020005","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To determine whether immunotherapy of chronic HIV-1 infection can prevent or attenuate viremia upon antiviral discontinuation.</p><p><strong>Design: </strong>This was a Phase II randomized, partially double blinded, 2x2 factorial study of three steps of 12 wk/step. Step I involved four groups: (1) vaccine placebo, (2) vaccine (ALVAC, vCP1452), (3) placebo + interleukin 2 (IL-2), and (4) vaccine + IL-2. Step II involved a 12-wk diagnostic treatment interruption (DTI). Step III involved an extension of the DTI for an additional 12 wk.</p><p><strong>Setting: </strong>The Weill-Cornell General Clinical Research Center.</p><p><strong>Participants: </strong>Chronically infected HIV-1 positive adults with undetectable HIV-1 levels and > 400 CD4+ T cells/microl.</p><p><strong>Interventions: </strong>An HIV canarypox vaccine (vCP1452) and vaccine placebo, administered every 4 wk for four doses, and low-dose IL-2 administered daily for 12-24 wk.</p><p><strong>Outcome measures: </strong>Primary endpoints: (1) Proportion of participants with undetectable plasma HIV RNA during trial Step II, (2) mean log10 HIV RNA copies/ml ([HIV]) from weeks 21-25, and (3) proportion of individuals eligible for trial Step III.</p><p><strong>Results: </strong>44 participants were randomized, but 16 withdrew or were withdrawn before completing Step II. As all participants underwent viral relapse in Step II, the study was terminated after 28 participants completed Step II. Among the four groups, there was no difference in mean [HIV] or the proportion of individuals with < log10 4.48 HIV; no difference between the mean [HIV] of the two groups that received ALVAC (n = 17) versus placebo (n = 11); and no significant difference between the mean [HIV] of the two groups that received IL-2 (n = 11) versus placebo (n = 17).</p><p><strong>Conclusions: </strong>Neither ALVAC (vCP1452) nor low-dose daily IL-2 nor their combination prevented the relapse of viremia upon discontinuation of antiviral therapy.</p>","PeriodicalId":87416,"journal":{"name":"PLoS clinical trials","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2007-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783674/pdf/","citationCount":"0","resultStr":"{\"title\":\"Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial.\",\"authors\":\"Kendall A Smith, Sofija Andjelic, Zoran Popmihajlov, Liza Kelly-Rossini, Aquanette Sass, Martin Lesser, Steven Benkert, Cory Waters, Joyce Ruitenberg, Paul Bellman\",\"doi\":\"10.1371/journal.pctr.0020005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To determine whether immunotherapy of chronic HIV-1 infection can prevent or attenuate viremia upon antiviral discontinuation.</p><p><strong>Design: </strong>This was a Phase II randomized, partially double blinded, 2x2 factorial study of three steps of 12 wk/step. Step I involved four groups: (1) vaccine placebo, (2) vaccine (ALVAC, vCP1452), (3) placebo + interleukin 2 (IL-2), and (4) vaccine + IL-2. Step II involved a 12-wk diagnostic treatment interruption (DTI). Step III involved an extension of the DTI for an additional 12 wk.</p><p><strong>Setting: </strong>The Weill-Cornell General Clinical Research Center.</p><p><strong>Participants: </strong>Chronically infected HIV-1 positive adults with undetectable HIV-1 levels and > 400 CD4+ T cells/microl.</p><p><strong>Interventions: </strong>An HIV canarypox vaccine (vCP1452) and vaccine placebo, administered every 4 wk for four doses, and low-dose IL-2 administered daily for 12-24 wk.</p><p><strong>Outcome measures: </strong>Primary endpoints: (1) Proportion of participants with undetectable plasma HIV RNA during trial Step II, (2) mean log10 HIV RNA copies/ml ([HIV]) from weeks 21-25, and (3) proportion of individuals eligible for trial Step III.</p><p><strong>Results: </strong>44 participants were randomized, but 16 withdrew or were withdrawn before completing Step II. As all participants underwent viral relapse in Step II, the study was terminated after 28 participants completed Step II. Among the four groups, there was no difference in mean [HIV] or the proportion of individuals with < log10 4.48 HIV; no difference between the mean [HIV] of the two groups that received ALVAC (n = 17) versus placebo (n = 11); and no significant difference between the mean [HIV] of the two groups that received IL-2 (n = 11) versus placebo (n = 17).</p><p><strong>Conclusions: </strong>Neither ALVAC (vCP1452) nor low-dose daily IL-2 nor their combination prevented the relapse of viremia upon discontinuation of antiviral therapy.</p>\",\"PeriodicalId\":87416,\"journal\":{\"name\":\"PLoS clinical trials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-01-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783674/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PLoS clinical trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1371/journal.pctr.0020005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1371/journal.pctr.0020005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的确定针对慢性 HIV-1 感染的免疫疗法能否在停用抗病毒药物后预防或减轻病毒血症:这是一项 II 期随机、部分双盲、2x2 因式研究,分三步进行,每步 12 周。第一步分为四组:(1) 疫苗安慰剂组;(2) 疫苗(ALVAC,vCP1452)组;(3) 安慰剂+白细胞介素 2 (IL-2) 组;(4) 疫苗+IL-2 组。第二步是为期 12 周的诊断性治疗中断(DTI)。第三步是将诊断治疗延长 12 周:魏尔-康奈尔综合临床研究中心:慢性感染的 HIV-1 阳性成人,HIV-1 检测不到,CD4+ T 细胞大于 400 个/毫升:干预措施:HIV加那利痘疫苗(vCP1452)和疫苗安慰剂,每4周接种一次,共接种4次,低剂量IL-2每天接种12-24周:主要终点:(1) 在试验步骤 II 中检测不到血浆 HIV RNA 的参与者比例;(2) 第 21-25 周的平均 log10 HIV RNA 拷贝数/毫升([HIV]);(3) 符合试验步骤 III 的参与者比例:44 名参与者被随机选中,但有 16 人退出或在完成步骤 II 之前退出。由于所有参与者在步骤 II 中均出现病毒复发,研究在 28 名参与者完成步骤 II 后终止。在四组参与者中,平均[HIV]值或HIV值小于log10 4.48的人数比例没有差异;接受ALVAC治疗的两组参与者(n = 17)的平均[HIV]值与接受安慰剂治疗的两组参与者(n = 11)的平均[HIV]值没有差异;接受IL-2治疗的两组参与者(n = 11)的平均[HIV]值与接受安慰剂治疗的两组参与者(n = 17)的平均[HIV]值没有显著差异:结论:无论是ALVAC(vCP1452)还是低剂量每日IL-2,抑或是两者的联合应用,都不能防止停止抗病毒治疗后病毒血症的复发。
Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial.
Objectives: To determine whether immunotherapy of chronic HIV-1 infection can prevent or attenuate viremia upon antiviral discontinuation.
Design: This was a Phase II randomized, partially double blinded, 2x2 factorial study of three steps of 12 wk/step. Step I involved four groups: (1) vaccine placebo, (2) vaccine (ALVAC, vCP1452), (3) placebo + interleukin 2 (IL-2), and (4) vaccine + IL-2. Step II involved a 12-wk diagnostic treatment interruption (DTI). Step III involved an extension of the DTI for an additional 12 wk.
Setting: The Weill-Cornell General Clinical Research Center.
Participants: Chronically infected HIV-1 positive adults with undetectable HIV-1 levels and > 400 CD4+ T cells/microl.
Interventions: An HIV canarypox vaccine (vCP1452) and vaccine placebo, administered every 4 wk for four doses, and low-dose IL-2 administered daily for 12-24 wk.
Outcome measures: Primary endpoints: (1) Proportion of participants with undetectable plasma HIV RNA during trial Step II, (2) mean log10 HIV RNA copies/ml ([HIV]) from weeks 21-25, and (3) proportion of individuals eligible for trial Step III.
Results: 44 participants were randomized, but 16 withdrew or were withdrawn before completing Step II. As all participants underwent viral relapse in Step II, the study was terminated after 28 participants completed Step II. Among the four groups, there was no difference in mean [HIV] or the proportion of individuals with < log10 4.48 HIV; no difference between the mean [HIV] of the two groups that received ALVAC (n = 17) versus placebo (n = 11); and no significant difference between the mean [HIV] of the two groups that received IL-2 (n = 11) versus placebo (n = 17).
Conclusions: Neither ALVAC (vCP1452) nor low-dose daily IL-2 nor their combination prevented the relapse of viremia upon discontinuation of antiviral therapy.